Net Cash Provided by (Used in) Operating Activities |
-22.9K |
USD |
+43.2% |
Q3 2024 |
Q1 2025 |
Net Cash Provided by (Used in) Financing Activities |
0 |
USD |
-100% |
Q3 2023 |
Q1 2024 |
Common Stock, Shares Authorized |
500M |
shares |
-93.3% |
Q2 2025 |
FY 2025 |
Common Stock, Shares, Issued |
20.1M |
shares |
+1.64% |
Q2 2025 |
FY 2025 |
Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q2 2025 |
FY 2025 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
-22.9K |
USD |
+43.2% |
Q3 2024 |
Q1 2025 |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
14.6K |
USD |
-66.4% |
Q2 2025 |
FY 2025 |
Deferred Tax Assets, Valuation Allowance |
1.98M |
USD |
+5.49% |
Q2 2025 |
FY 2025 |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
-553K |
USD |
-299% |
Q2 2025 |
FY 2025 |
Additional Paid in Capital |
9.15M |
USD |
+1.48% |
Q2 2025 |
FY 2025 |
Deferred Tax Assets, Net of Valuation Allowance |
0 |
USD |
|
Q2 2025 |
FY 2025 |
Interest Expense |
38.3K |
USD |
-37.9% |
Q2 2025 |
FY 2025 |